EPS of $20 by 2025? Progress and Profile to Power Paradigm’s Share Price

Paradigm Biopharmaceuticals (PAR.ASX) have $108M in cash, no debt and are well advanced in the progression of clinical trials in addressable markets worth up to as much as $36B p.a. The next two years are particularly exciting for Paradigm Biopharmaceuticals as they are set to announce: Complete recruitment of 1150 patients for the stage 3-clinical […]